The more I read the scientific literature and the more I understand the muti-faceted aspects of AML the more convinced I become that TKIs with muti-kinase activity are the most valuable approach. Whether LUX or TUSP has the optimal multi-TKI profile or not is certainly open to debate, but many of the targets hit by these agents are involved in AML.
We do not have a lot of data yet but I find it interesting that TUSP seems to be active against NPM1 and MLL-fusion driven AMLs. These two drivers are being targeted by the new Menin inhibitors. The menin inhibitors and TUSP seem to have similar ORRs. The mechanism of the menin inhibitors is understood, not so much for TUSP in these specific populations. So far, TUSP seems to have less side effects.
News 
Market Data 
Discover 
